✦ LIBER ✦

Aflibercept for Age-Related Macular Degeneration: A Game-Changer or Quiet Addition?

✍ Scribed by David J. Browning; Peter K. Kaiser; Philip J. Rosenfeld; Michael W. Stewart

Book ID: 116203261
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 197 KB
Volume: 154
Category: Article
ISSN: 0002-9394
DOI: 10.1016/j.ajo.2012.04.020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intravitreal Aflibercept for Treatment-R

Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-related Macular Degeneration

✍ Chang, Andrew A.; Li, Haitao; Broadhead, Geoffrey K.; Hong, Thomas; Schlub, Timo 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 198 KB

Conversion to Aflibercept For Chronic Re

Conversion to Aflibercept For Chronic Refractory Or Recurrent Neovascular Age-Related Macular Degeneration

✍ Yonekawa, Yoshihiro; Andreoli, Christopher; Miller, John B.; Loewenstein, John I 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 992 KB

Cost-Minimization Analysis of Intravitre

Cost-Minimization Analysis of Intravitreal Aflibercept (IVT-AFL) for Neovascular Age-Related Macular Degeneration in Spain

✍ Garcia-Layana, A.; Ortega, A.; Ruiz-Moreno, J.M.; Figueroa, M.S.; Farres, J.; Me 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Aflibercept: a Potent Vascular Endotheli

Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases

✍ Raafay Sophie, Abeer Akhtar, Yasir J. Sepah, Mohamed Ibrahim, Millena Bittencour 📂 Article 📅 2012 🏛 Springer Healthcare Communications 🌐 English ⚖ 854 KB

Serum and Plasma Vascular Endothelial Gr

Serum and Plasma Vascular Endothelial Growth Factor Concentrations Before and After Intravitreal Injection of Aflibercept or Ranibizumab for Age-Related Macular Degeneration

✍ Wang, Xiying; Sawada, Tomoko; Sawada, Osamu; Saishin, Yoshitsugu; Liu, Ping; Ohj 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 834 KB

Initial experience with aflibercept in t

Initial experience with aflibercept in the management of patients with wet age-related macular degeneration refractory to ranibizumab and/or bevacizumab

✍ Cervera, R.E.; Castro, V.; Montero, J.; Torralba, C.; Gracia, A. 📂 Article 📅 2014 🏛 Elsevier ⚖ 387 KB